BACKGROUND: The Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) develops progressive forms of prostate cancer. Due to the lack of a validated non-invasive methodology, pathology has been so far the most common parameter evaluated in efficacy studies. METHODS: We studied by magnetic resonance imaging (MRI) 210 mice that were repeatedly measured up to 33 weeks of age in order to stage prostate tumors and follow pathological progression in single animals. A pre-clinical trial with doxorubicin was also performed. RESULTS: Progressive forms of cancer (well and poorly differentiated (PD) adenocarcinomas) were easily recognized on MR images and MRI findings were validated against histopathological analysis. Age at tumor onset was different for the two tumoral forms. Doxorubicin treatment caused a strong reduction in tumor volume. CONCLUSIONS: Prostate cancer in TRAMP mice is multifocal and heterogeneous: a non-invasive methodology such as MRI facilitates the rational design of translational pre-clinical trials in this widely used animal model.
BACKGROUND: The Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) develops progressive forms of prostate cancer. Due to the lack of a validated non-invasive methodology, pathology has been so far the most common parameter evaluated in efficacy studies. METHODS: We studied by magnetic resonance imaging (MRI) 210 mice that were repeatedly measured up to 33 weeks of age in order to stage prostate tumors and follow pathological progression in single animals. A pre-clinical trial with doxorubicin was also performed. RESULTS: Progressive forms of cancer (well and poorly differentiated (PD) adenocarcinomas) were easily recognized on MR images and MRI findings were validated against histopathological analysis. Age at tumor onset was different for the two tumoral forms. Doxorubicin treatment caused a strong reduction in tumor volume. CONCLUSIONS:Prostate cancer in TRAMPmice is multifocal and heterogeneous: a non-invasive methodology such as MRI facilitates the rational design of translational pre-clinical trials in this widely used animal model.
Authors: Jody T Mack; Kristi L Helke; Gabrielle Normand; CoDanielle Green; Danyelle M Townsend; Kenneth D Tew Journal: Cancer Lett Date: 2010-10-30 Impact factor: 8.679
Authors: Cornelius von Morze; Galen Reed; Peter Shin; Peder E Z Larson; Simon Hu; Robert Bok; Daniel B Vigneron Journal: J Magn Reson Date: 2011-05-01 Impact factor: 2.229
Authors: Nadia Guerra; Ying Xim Tan; Nathalie T Joncker; Augustine Choy; Fermin Gallardo; Na Xiong; Susan Knoblaugh; Dragana Cado; Norman M Greenberg; Norman R Greenberg; David H Raulet Journal: Immunity Date: 2008-04 Impact factor: 31.745
Authors: Ali S Arbab; Adarsh Shankar; Nadimpalli R S Varma; Dorrah Deeb; Xiaohua Gao; A S M Iskander; Branislava Janic; Meser M Ali; Subhash C Gautam Journal: BMC Med Imaging Date: 2011-12-13 Impact factor: 1.930